Avoro Capital Increases Stake in Whitehawk Therapeutics via $25M PIPE Financing and Warrants

On May 12, 2026, Avoro Capital Advisors LLC and its affiliates entered into a Securities Purchase Agreement with Whitehawk Therapeutics, Inc. (WHWK) as part of a 2026 PIPE Financing. Avoro Life Sciences Fund LLC acquired 6,377,714 pre-funded warrants for approximately $25 million using working capital. These warrants have an exercise price of $0.0001 per share and are immediately exercisable, subject to a 19.99% beneficial ownership blocker. Following this transaction, Avoro Capital Advisors LLC reports beneficial ownership of 15,893,516 shares, representing 19.99% of the outstanding common stock (after giving effect to the blocker). The reporting persons also entered into a Registration Rights Agreement requiring the issuer to file a resale registration statement within 30 days of closing. This filing represents Amendment No. 5 to their original Schedule 13D, reflecting the increased position through the newly acquired warrants. Behzad Aghazadeh, associated with the funds, also reports a combined interest subject to the same regulatory ownership cap.